Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246415 | 0.81 | CCR1 (0.39) | KCNH2 | |
| SCHEMBL29865866 | 0.81 | CCR1 (0.39) | KCNH2 | |
| SCHEMBL3748371 | 0.79 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL29191259 | 0.76 | MCHR1 (0.40) | KCNH2 | |
| SCHEMBL12615482 | 0.76 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL2650003 | 0.76 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL30070612 | 0.76 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL29851211 | 0.76 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL1143101 | 0.76 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL29851025 | 0.76 | KCNH2 (0.35) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2445900-B1 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | AMGEN INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2445900-A2 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-1997027184-A1 | SULPHOXIDE- AND SULPHONE-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES | VOGELBACHER, UWE, JOSEF | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KCNH2 3280/4885 |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KCNH2 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.